<DOC>
	<DOCNO>NCT00803686</DOCNO>
	<brief_summary>This study conduct assess plasma CTx-1 concentration dose night compare result obtain placebo control commercially available nasal calcitonin .</brief_summary>
	<brief_title>A Study Oral Calcitonin Given Night Healthy Postmenopausal Women</brief_title>
	<detailed_description>Timing dose recombinant salmon calcitonin ( rsCT ) important effect reduction osteoclast activity . It theorize dose administer bedtime effective dose administer morning . See protocol summary information .</detailed_description>
	<mesh_term>Salmon calcitonin</mesh_term>
	<mesh_term>Calcitonin</mesh_term>
	<mesh_term>Calcitonin Gene-Related Peptide</mesh_term>
	<criteria>Inclusion Criteria Postmenopausal female , good health ( least five year since last menses ) . Age great equal 45 year old less equal 70 year old Weight Â± 20 % Metropolitan Life weight table . Plasma CTx1 great equal 0.25 ng/ml . Total calcium , phosphorus , magnesium within normal range . Willing able comply study requirement . Willing able sign write informed consent . Negative urine pregnancy test screening . Negative Screen Hepatitis B C , HIV drug abuse . History parathyroid , thyroid , pituitary adrenal disease . History musculoskeletal disease . History gastroesophageal reflux disease ( GERD ) significant gastrointestinal disorder . History cancer within 5 year enrollment basal cell carcinoma . History regular use NonSteroidal Antiinflammatory Drug ( NSAID ) . History surgery within 60 day enrollment . History hypersensitivity allergy ( seasonal allergy ) within year enrollment include known sensitivity active ingredient excipients study medication . Use concomitant medication acetaminophen within 7 day enrollment anticipate need use concomitant medication study . Use bisphosphonates within 6 month , SERMS , estrogen estrogenlike drug 2 month , calcitonin 1 month . Presence clinically significant illness . Unwilling unable comply study requirement . Unwilling unable sign write , informed consent . History drug alcohol abuse . Participation clinical study investigational drug within 60 day enrollment . Plasma CTx1 le 0.25 ng/mL .</criteria>
	<gender>Female</gender>
	<minimum_age>45 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>June 2014</verification_date>
</DOC>